|                              | Not seroconverted (N=10) | Seroconverted (N=161) | OR (univariable) | OR (multivariable) |
|------------------------------|--------------------------|-----------------------|------------------|------------------|
| **Age (SD)**                 | 67.2 (7.9)               | 65.0 (11.6)           | 0.98 (0.91-1.04, p=0.547) | 0.97 (0.90-1.04, p=0.442) |
| **Gender (%)**               |                          |                       |                  |                  |
| Male                         | 5 (7.1)                  | 65 (92.9)             |                  |                  |
| Female                       | 5 (5.0)                  | 96 (95.0)             | 1.48 (0.40-5.51, p=0.550) | 0.99 (0.19-4.76, p=0.986) |
| **BMI (SD)**                 | 27.3 (4.7)               | 25.1 (4.4)            | 0.91 (0.80-1.94, p=0.137) | 0.89 (0.77-1.02, p=0.080) |
| **ECOG (%)**                 |                          |                       |                  |                  |
| <=2                          | 8.0 (4.8)                | 157 (95.2)            |                  |                  |
| >2                           | 2 (33.3)                 | 4 (66.7)              | 0.10 (0.02-0.81, p=0.015) | 0.07 (0.01-0.64, p=0.012) |
| **Chemotherapy (%)**         |                          |                       |                  |                  |
| No                           | 2 (3.3)                  | 59 (96.7)             | 0.43 (0.06-1.79, p=0.299) | 0.18 (0.02-1.47, p=0.127) |
| Yes                          | 8 (7.3)                  | 102 (92.7)            |                  |                  |
| **Immunotherapy (%)**        |                          |                       |                  |                  |
| No                           | 9 (6.1)                  | 139 (93.9)            |                  |                  |
| Yes                          | 1 (4.3)                  | 22 (95.7)             | 1.42 (0.25-26.91, p=0.743) | 0.44 (0.04-11.07, p=0.535) |
| **Targeted therapy (%)**     |                          |                       |                  |                  |
| No                           | 6 (5.7)                  | 100 (94.3)            |                  |                  |
| Yes                          | 4 (6.2)                  | 61 (93.8)             | 0.92 (0.25-3.70, p=0.894) | 0.48 (0.10-2.53, p=0.364) |
| **Endocrine therapy (%)**    |                          |                       |                  |                  |
| No                           | 9 (5.7)                  | 150 (94.3)            | 0.66 (0.11-12.73, p=0.705) | 0.23 (0.02-5.59, p=0.267) |